HopeStage
Back to all studies
CompletedNCT01305408

Armodafinil Added to Mood Stabilizers for Depression With Bipolarity

About this title

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Read the official source — NCT01305408
Medication studyAges 18–65Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Birmingham and 129 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2011
Recruitment status
Completed
Enrollment listed in the registry
399
Sponsor
Cephalon
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Argentina, Brazil, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT01305408
Official title
Show the full official title

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Birmingham, United States · Sherman Oaks, United States · Temecula, United States

97 more locations
  • Jacksonville Beach, United States
  • Lauderhill, United States
  • Tampa, United States
  • Atlanta, United States
  • Park Ridge, United States
  • Indianapolis, United States
  • Lafayette, United States
  • Watertown, United States
  • Brooklyn, United States
  • New York, United States
  • Staten Island, United States
  • Wilmington, United States
  • Cincinnati, United States
  • Toledo, United States
  • Oklahoma City, United States
  • Allentown, United States
  • DeSoto, United States
  • Friendswood, United States
  • Salt Lake City, United States
  • Kirkland, United States
  • Spokane, United States
  • Buenos Aires, Argentina
  • Córdoba, Argentina
  • Córdoba Capital, Argentina
  • La Plata, Argentina
  • La Plata, Buenos Aires, Argentina
  • Mendoza, Argentina
  • Rosario, Argentina
  • Belo Horizonte, Brazil
  • Curitiba-Parana, Brazil
  • Distrito de Rubiao Junior, Brazil
  • Itapira -Sao Paulo, Brazil
  • Rio de Janeiro, Brazil
  • Salvador, Brazil
  • São Paulo, Brazil
  • Burgas, Bulgaria
  • Kardzhali, Bulgaria
  • Kazanlak, Bulgaria
  • Pazardzhik, Bulgaria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Rijeka, Croatia
  • Split, Croatia
  • Zagreb, Croatia
  • Helsinki, Finland
  • Kangasala, Finland
  • Turku, Finland
  • Achim, Germany
  • Berlin, Germany
  • Cologne, Germany
  • Dresden, Germany
  • Freiburg im Breisgau, Germany
  • Mittweida, Germany
  • Budapest, Hungary
  • Győr, Hungary
  • Nagykálló, Hungary
  • Catania, Italy
  • Florence, Italy
  • Genova, Italy
  • Lido Di Camaiore(LU), Italy
  • Naples, Italy
  • Pisa, Italy
  • Roma, Italy
  • Bialystok, Poland
  • Gdansk, Poland
  • Gdynia, Poland
  • Krakow, Poland
  • Skorzewo, Poland
  • Szczecin, Poland
  • Tuszyn, Poland
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Niš, Serbia
  • Novi Kneževac, Serbia
  • Bojnice, Slovakia
  • Bratislava, Slovakia
  • Rimavská Sobota, Slovakia
  • Rožňava, Slovakia
  • Trenčín, Slovakia
  • Cape Town, South Africa
  • Centurion, South Africa
  • Johannesburg, South Africa
  • Paarl, South Africa
  • Pretoria, South Africa
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Luhansk, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Poltava, Ukraine
  • S. Oleksandrivka, Ukraine
  • Vinnytsia, Ukraine

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Cephalon.

Did this study involve medication?

Yes. The study involved medication, including Armodafinil and Placebo.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies